Peptide Safety: Side Effects, Risks, Drug Interactions, and Harm Reduction

Safety should be the first thing you evaluate -- not the last. Before comparing efficacy, cost, or convenience, you need to know what a peptide can do to you, not just what it can do for you.

This guide covers what the published research shows about peptide side effects, serious adverse events, drug interactions, long-term safety, and harm reduction strategies. We cover FDA-approved GLP-1 agonists, research-only healing peptides, and growth hormone secretagogues.

This is not medical advice. We are not physicians. The information on this page is for educational and informational purposes only. It is based on published clinical trial data, FDA labeling, preclinical research, and community-reported experiences. Nothing here replaces the guidance of a qualified healthcare provider. Do not start, stop, or change any peptide or medication without consulting your doctor. See our full medical disclaimer.

Where clinical data exists, we cite it. Where it does not, we say so. The absence of reported harm is not proof of safety -- it often means the research has not been done.

---

Why Safety Comes First

The peptide space moves fast. New compounds emerge regularly. Online communities share protocols and experiences in real time. Telehealth platforms prescribe peptides with minimal oversight. Compounding pharmacies produce formulations with varying quality controls.

In this environment, it is easy to focus on outcomes and skip the safety analysis. That is a mistake.

Here is what responsible peptide evaluation looks like:

1. What is the evidence tier? FDA-approved drugs have extensive safety data from thousands of patients. Research peptides may have only animal studies.
2. What are the known risks? Every compound has a risk profile. Understanding it lets you make informed decisions.
3. What do we not know? For many peptides, the honest answer to "Is this safe long-term?" is: we do not have enough data to say.
4. What can you do to reduce risk? Even with FDA-approved medications, how you use them matters. Dose titration, medical supervision, and monitoring all affect outcomes.

We built this resource to give you the safety information in one place, organized by peptide class, with evidence quality clearly labeled.

---

Common Side Effects by Peptide Class

GLP-1 Receptor Agonists

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) have the most extensive safety data of any peptide class. Clinical trial programs enrolled tens of thousands of participants with follow-up periods extending to two or more years.

Gastrointestinal Side Effects

GI side effects are the most common adverse events for all GLP-1 agonists. They are a direct consequence of how these drugs work -- slowing gastric emptying and altering gut motility.

Nausea

• Most commonly reported side effect across all GLP-1 trials
• Reported in 20-44% of participants at therapeutic doses (varies by compound and dose)
• Typically most intense during dose escalation
• Usually improves within 4-8 weeks at a stable dose
• More common with tirzepatide at higher doses than with semaglutide at equivalent efficacy doses
• Tirzepatide Nausea: How Long Does It Last?

Vomiting

• Reported in 5-18% of trial participants depending on compound and dose
• More common during dose escalation
• Can usually be managed by slower titration

Diarrhea and Constipation

• Both are reported. Some patients experience diarrhea; others experience constipation. Some experience both at different points.
• Rates range from 5-20% across trials
• Adequate hydration and fiber intake can help manage both

Decreased Appetite

• This is technically the intended effect, but some patients experience appetite reduction so severe it becomes problematic
• Can lead to inadequate nutrition if not monitored

For the complete side effect profile: GLP-1 Side Effects: What to Expect.

Other Common GLP-1 Side Effects

• Headache -- reported in 10-14% of participants in some trials
• Fatigue -- reported by some users, though rates vary across trials
• Injection site reactions -- mild redness, swelling, or itching at the injection site. Usually transient.
• Dizziness -- occasional, particularly during initial titration
• Hair loss -- reported by some users. The connection to GLP-1 drugs specifically (vs. rapid weight loss in general) is debated. See: Semaglutide and Hair Loss

For long-term side effect data: Semaglutide Side Effects Long-Term.

Healing Peptides (BPC-157, TB-500)

Published human safety data for BPC-157 and TB-500 is extremely limited. What follows is based on animal studies and community-reported experiences. Treat it accordingly.

BPC-157 reported side effects:

• Nausea (occasional, usually mild)
• Headache
• Dizziness
• Injection site discomfort
• GI discomfort (when taken orally)

TB-500 reported side effects:

• Headache
• Fatigue or lethargy
• Injection site irritation
• Occasional lightheadedness

Both peptides are generally described as "well-tolerated" in the limited published literature and in user reports. But this claim carries a major caveat: we do not have systematic human safety data from controlled trials. The absence of widely reported problems is not the same as demonstrated safety.

Growth Hormone Secretagogues (CJC-1295, Ipamorelin, MK-677)

GH secretagogues stimulate the pituitary gland to release more growth hormone. Side effects are generally related to elevated GH and IGF-1 levels.

Common reported side effects:

• Water retention -- swollen hands, feet, or face. One of the most frequently reported effects.
• Tingling or numbness (paresthesia) -- particularly in hands and fingers. Related to fluid shifts.
• Joint stiffness -- associated with elevated GH levels
• Increased hunger -- particularly with MK-677 (ibutamoren), which acts as a ghrelin mimetic
• Elevated blood sugar -- GH is a counter-regulatory hormone to insulin. Extended use can impair glucose tolerance.
• Fatigue -- some users report unusual tiredness, particularly early in use
• Headache -- occasionally reported during initial use

MK-677 specific concern: MK-677 (ibutamoren) is an oral GH secretagogue that significantly increases GH and IGF-1 levels. It also raises fasting glucose and insulin levels. People with impaired glucose tolerance, insulin resistance, or diabetes should approach MK-677 with particular caution and medical supervision.

---

Serious Adverse Events to Watch For

These are less common but potentially dangerous adverse events reported in clinical trials or post-market surveillance. Their rarity does not diminish their importance.

Pancreatitis

Both semaglutide and tirzepatide carry label warnings for pancreatitis. Rates in clinical trials were low (generally less than 1%), but the condition is serious and can be life-threatening.

Warning signs:

• Severe, persistent abdominal pain (often radiating to the back)
• Nausea and vomiting that does not resolve
• Abdominal tenderness

What to do: Stop the medication and seek medical attention immediately if you experience severe abdominal pain that does not go away.

Gallbladder Events

Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported at higher rates in GLP-1 trial participants vs placebo. This may be related to rapid weight loss rather than the drug mechanism itself -- gallstones are a known risk of rapid weight loss regardless of the method.

In the STEP trials, gallbladder-related events occurred in approximately 1.5-2.5% of semaglutide-treated participants.

Intestinal Obstruction

Rare reports of ileus (intestinal obstruction) exist for GLP-1 agonists. The mechanism -- slowed gastric emptying -- can theoretically contribute to bowel obstruction in predisposed individuals. This is rare but serious.

Allergic Reactions

Anaphylaxis and serious hypersensitivity reactions have been reported with GLP-1 agonists, though they are rare. Angioedema (swelling of face, lips, tongue, or throat) requires immediate medical attention.

Kidney Injury

Acute kidney injury has been reported in some cases, often associated with severe GI symptoms (vomiting, diarrhea) leading to dehydration. Adequate hydration is important, particularly during dose titration when GI side effects are most common.

Thyroid Concerns

This is covered in depth in the Cancer Risk section below. In short: rodent studies showed thyroid C-cell tumors with GLP-1 agonists. This has not been confirmed in humans, but these drugs carry a boxed warning and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

See: Peptides and Thyroid Problems.

---

Drug Interactions

Peptides can interact with other medications. This section covers the most clinically relevant interactions.

GLP-1 Agonists and Oral Medications

Because GLP-1 agonists slow gastric emptying, they can affect the absorption of oral medications taken at the same time. This is particularly relevant for:

• Oral contraceptives -- delayed absorption could reduce effectiveness. Some guidelines recommend using backup contraception during initial GLP-1 titration.
• Levothyroxine -- thyroid medication absorption may be altered. Monitor thyroid levels and adjust timing if needed.
• Antibiotics -- oral antibiotics that require specific absorption timing may be affected.
• Oral semaglutide (Rybelsus) -- must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before any other food, drink, or oral medication. This is a critical administration requirement, not optional.

General rule: If you take oral medications with narrow therapeutic windows (meaning small changes in blood levels matter), discuss timing with your prescriber when starting a GLP-1 agonist.

Insulin and Blood Sugar-Lowering Drugs

GLP-1 agonists lower blood sugar. Combining them with insulin, sulfonylureas, or other glucose-lowering medications increases the risk of hypoglycemia. Dose adjustments are often necessary.

This is particularly important for people with type 2 diabetes who are already on multiple glucose-lowering agents. Adding a GLP-1 agonist without adjusting existing medications can lead to dangerously low blood sugar.

Blood Thinners

Some peptides (particularly BPC-157) may affect blood clotting pathways based on preclinical data. If you are on anticoagulants (warfarin, heparin, DOACs) or antiplatelet agents, discuss any peptide use with your physician.

This is a theoretical concern based on BPC-157's effects on nitric oxide and vascular pathways in animal models. There is not enough human data to quantify the risk precisely, which is itself a reason for caution.

GH Secretagogues and Diabetes Medications

Growth hormone is a counter-regulatory hormone to insulin. Elevated GH levels can raise blood sugar. If you have diabetes or prediabetes and are considering GH secretagogues (CJC-1295, Ipamorelin, MK-677), monitor glucose closely and discuss with your endocrinologist.

MK-677 in particular has been shown to raise fasting glucose and insulin levels in published studies. This is not a subtle effect -- it is consistent and clinically relevant.

Anesthesia Considerations

GLP-1 agonists slow gastric emptying, which matters for surgical procedures. Patients on semaglutide or tirzepatide may have food remaining in their stomach longer than expected. This increases the risk of aspiration during anesthesia.

The American Society of Anesthesiologists has issued guidance recommending that patients discuss GLP-1 use with their surgical team before any procedure requiring anesthesia. Some protocols recommend holding GLP-1 agonists for one to three weeks before elective surgery, depending on the compound and dose.

If you are on any GLP-1 agonist and are scheduled for surgery, tell your anesthesiologist.

---

Long-Term Safety Data: What We Know and What We Do Not

What We Know (GLP-1 Class)

Semaglutide has the longest published safety record among current GLP-1 weight loss agents:

• STEP 5 trial: 2-year data showing sustained efficacy with continued safety monitoring
• SELECT trial: cardiovascular outcomes trial demonstrating a 20% reduction in major adverse cardiovascular events (MACE) in people with existing cardiovascular disease and obesity -- a significant positive safety signal
• Post-market surveillance data from millions of prescriptions since Ozempic's approval in 2017

Tirzepatide has strong but shorter published safety data:

• SURMOUNT trials: up to 72-week data
• SURPASS trials (diabetes): up to 2 years
• Post-market surveillance accumulating since Mounjaro's approval in 2022

What We Do Not Know

Long-term effects beyond 2-3 years. Most trial data extends to 72-104 weeks. We do not have 5-year, 10-year, or lifetime safety data for any of the newer GLP-1 agonists used for weight management.

Effects of stopping and restarting. Weight regain after stopping GLP-1 agonists is well-documented. But the safety implications of cycling on and off these drugs (multiple start-stop-start cycles) have not been studied systematically.

Safety in younger populations. Most trial participants have been adults 18-65. Data in adolescents is emerging but limited. Long-term safety implications of starting these drugs at younger ages are unknown.

Pregnancy outcomes after use. While GLP-1 agonists should be stopped before pregnancy (see below), the effects of prior long-term use on subsequent pregnancy outcomes are not well-studied.

Research peptides -- almost everything. For BPC-157, TB-500, CJC-1295, Ipamorelin, and most other research peptides, we do not have meaningful long-term human safety data. Period. Anyone who tells you these compounds are "proven safe" for long-term human use is making a claim not supported by published evidence.

---

Cancer Risk Evaluation

Thyroid C-Cell Concerns

This is one of the most discussed safety topics in the GLP-1 space, and it deserves careful explanation.

The rodent data: In preclinical studies, semaglutide, tirzepatide, and liraglutide all caused thyroid C-cell tumors (medullary thyroid carcinoma) in rodents. This finding led to a boxed warning on all GLP-1 receptor agonist labels.

The human data: As of the most recent published evidence, thyroid C-cell tumors have not been confirmed as a consequence of GLP-1 use in humans. Multiple analyses of large patient databases have not found a significant increase in medullary thyroid carcinoma rates among GLP-1 users.

Why the discrepancy? Rodent thyroid C-cells express GLP-1 receptors at much higher density than human thyroid C-cells. The rodent response may not translate to humans. But "may not" is not "does not" -- which is why the boxed warning remains.

Practical implications:

• GLP-1 agonists are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• If you notice a lump in your neck, hoarseness, difficulty swallowing, or shortness of breath while on a GLP-1 agonist, report it to your doctor immediately
• Routine thyroid monitoring is reasonable, though not universally recommended by all guidelines

For the full analysis: Can Peptides Cause Cancer? and Peptides and Thyroid Problems.

Pancreatic Cancer Concerns

Early concerns about a potential link between GLP-1 agonists and pancreatic cancer have not been supported by subsequent large-scale analyses. The SELECT trial and multiple observational studies have not shown an increased risk. However, long-term surveillance continues.

Growth Hormone and Cancer Risk

Elevated growth hormone and IGF-1 levels have been associated with increased cancer risk in epidemiological studies. This is relevant for people using GH secretagogues (CJC-1295, Ipamorelin, MK-677) or exogenous growth hormone.

The relationship is complex:

• Some studies show an association between higher IGF-1 levels and increased risk of certain cancers (prostate, breast, colorectal)
• The causal relationship is not established -- correlation does not prove causation
• The levels achieved through GH secretagogue use may differ from the levels studied in epidemiological research
• People with a history of cancer should discuss GH-related peptides with their oncologist before use

---

Alcohol and Peptides

This is one of the most frequently asked practical questions. Here is what we know.

GLP-1 Agonists and Alcohol

There is no absolute contraindication to moderate alcohol consumption while on GLP-1 agonists. However, several factors warrant caution:

• Nausea amplification -- GLP-1 agonists already cause nausea in many users. Alcohol can worsen it.
• Hypoglycemia risk -- alcohol can lower blood sugar. Combined with a GLP-1 agonist (which also lowers blood sugar), the risk of hypoglycemia increases, particularly in people on additional diabetes medications.
• Dehydration -- alcohol is a diuretic. GLP-1 side effects (vomiting, diarrhea) can also cause dehydration. The combination increases dehydration risk.
• Reduced tolerance -- many GLP-1 users report significantly reduced alcohol tolerance. This is widely reported anecdotally and is consistent with the drug's effects on gastric emptying and central appetite regulation.
• Pancreatitis risk -- heavy alcohol use is an independent risk factor for pancreatitis. GLP-1 agonists carry a pancreatitis warning. Combining both risk factors is inadvisable.

For the full breakdown: Can You Drink Alcohol on Semaglutide?.

Research Peptides and Alcohol

There is no published research on interactions between alcohol and research peptides like BPC-157, TB-500, or GH secretagogues. The absence of data is not an endorsement of safety -- it means the question has not been studied.

General harm reduction principle: if you are using any peptide and choose to drink alcohol, moderate your intake, stay hydrated, and monitor how you feel.

---

Pregnancy and Peptides

This section is straightforward: do not use peptides during pregnancy or while trying to conceive, unless specifically directed by your physician.

GLP-1 Agonists

• Semaglutide and tirzepatide are contraindicated during pregnancy
• Animal studies have shown embryo-fetal harm (reduced growth, structural abnormalities)
• Manufacturers recommend stopping GLP-1 agonists at least 2 months before a planned pregnancy (semaglutide has a long half-life of approximately 1 week)
• If you become pregnant while on a GLP-1 agonist, contact your healthcare provider immediately

Research Peptides

• No published reproductive safety data exists for BPC-157, TB-500, CJC-1295, Ipamorelin, or most other research peptides
• Growth hormone-related peptides could theoretically affect fetal development, but this has not been studied
• The prudent approach: stop all research peptides before attempting conception

Breastfeeding

• It is unknown whether semaglutide, tirzepatide, or research peptides are excreted in human breast milk
• The safe assumption is to avoid peptide use while breastfeeding unless a physician has specifically evaluated the risk-benefit ratio

---

Harm Reduction Strategies

If you are using or considering peptides, these practices can reduce your risk of adverse outcomes. These apply whether you are using FDA-approved medications or research compounds.

Work With a Knowledgeable Provider

This is the single most important harm reduction strategy. A physician who understands peptides can:

• Evaluate whether a peptide is appropriate given your medical history
• Monitor bloodwork and health markers during use
• Adjust dosing based on your response and side effects
• Identify drug interactions with your existing medications
• Intervene quickly if problems arise

"I read about it online" is not a substitute for medical oversight.

Start Low, Go Slow

Every GLP-1 agonist protocol involves dose titration -- starting at a low dose and increasing gradually over weeks or months. This is not optional. It exists because:

• Side effects (especially GI) are dose-dependent
• Gradual titration improves tolerance
• Jumping to a high dose increases the risk of severe nausea, vomiting, and dehydration

This principle applies to research peptides too. If you are starting any new peptide, begin at the lower end of reported dosing ranges and increase only if tolerated.

Monitor Your Bloodwork

Regular lab work is essential for anyone using peptides. Key markers to track:

• Comprehensive metabolic panel (kidney and liver function, electrolytes, glucose)
• HbA1c (if on GLP-1 agonists or GH secretagogues)
• Lipid panel (cholesterol and triglycerides)
• Thyroid function (TSH, free T3, free T4 -- particularly relevant for GLP-1 users)
• IGF-1 (if using GH secretagogues)
• CBC (complete blood count)

How often? At minimum, baseline labs before starting, then every 3-6 months while on a peptide protocol. Your physician may recommend more frequent monitoring based on your situation.

Know When to Stop

Stop using any peptide and contact your healthcare provider if you experience:

• Severe, persistent abdominal pain
• Signs of allergic reaction (swelling of face/lips/tongue, difficulty breathing, rash)
• Persistent vomiting that prevents you from keeping fluids down
• Signs of dehydration (dark urine, dizziness, rapid heartbeat, confusion)
• A lump in your neck or persistent hoarseness
• Vision changes
• Signs of low blood sugar (shaking, sweating, confusion, rapid heartbeat)
• Any symptom that feels unusual or concerning

When in doubt, stop and call your doctor. No peptide outcome is worth a medical emergency.

Source Quality Matters

This is primarily relevant for research peptides and compounded formulations. Not all peptide sources are equal.

• FDA-approved brand-name drugs (Ozempic, Wegovy, Mounjaro, Zepbound) have the highest quality assurance. Manufacturing is FDA-regulated.
• Compounding pharmacies vary in quality. Look for 503B-registered facilities, which are subject to FDA oversight. State-regulated 503A pharmacies have less standardized oversight. Verify licensing through your state board of pharmacy.
• Research chemical suppliers have the widest quality range. Request a Certificate of Analysis (COA) from an independent third-party lab for each batch. Look for HPLC purity testing showing 98%+ and endotoxin (LAL) testing.

Red flags for any peptide source: no COA available, COA only from an in-house lab, medical claims on the website, prices dramatically below market rate, no batch tracking, or packaging that mimics pharmaceutical brands. Avoid suppliers who claim their research peptides "cure" or "treat" anything -- this violates federal law and signals unreliable operations.

---

When to See a Doctor

Beyond the emergency scenarios listed above, here are situations where you should consult a healthcare provider before or during peptide use.

Before Starting Any Peptide

See a doctor first if you have:

• A history of pancreatitis
• A personal or family history of medullary thyroid carcinoma or MEN 2
• Type 1 or type 2 diabetes (dose adjustments of existing medications may be needed)
• Kidney disease or impaired kidney function
• Liver disease
• A history of eating disorders (GLP-1 agonists' appetite-suppressing effects may not be appropriate)
• Gallbladder disease or prior gallbladder removal
• Gastroparesis or other GI motility disorders
• Any active cancer or cancer history
• Planned surgery within the next 1-3 months
• Pregnancy, planned pregnancy, or breastfeeding

During Peptide Use

See a doctor if you experience:

• Side effects that persist beyond 4-6 weeks at a stable dose
• Unintended weight loss beyond your target
• Signs of malnutrition (hair loss, fatigue, muscle wasting, cognitive changes)
• New or worsening depression or mood changes
• Persistent changes in bowel habits
• New medications prescribed by another provider (to check for interactions)

When Stopping

Discuss discontinuation with your provider rather than stopping abruptly. For GLP-1 agonists, gradual discontinuation may help manage the weight regain that commonly occurs after stopping. For GH secretagogues, abrupt cessation after extended use may cause temporary disruptions in natural GH production (though this is not well-studied).

---

Reporting Adverse Events

If you experience a serious adverse event from any peptide, reporting it serves a public health function. Your report becomes part of the safety data that helps identify risks for others.

FDA MedWatch

The FDA's MedWatch program accepts reports of serious adverse events from medications, including:

• Online: FDA MedWatch Safety Reporting
• Phone: 1-800-FDA-1088
• What to report: Any serious adverse event -- hospitalization, life-threatening reaction, permanent disability, death, or any event you consider medically significant

You do not need to prove the peptide caused the event. Suspected associations are reportable and valuable.

For Research Peptides

Research peptides are not FDA-approved drugs, which creates a reporting gap. No formal adverse event reporting system exists for research chemicals. However, you can still file a MedWatch report describing the product and event. Documenting your experience through your healthcare provider adds to the collective knowledge base.

Post-market surveillance depends on these reports. Real-world use reveals problems that controlled trials may miss. Every report counts, especially for newer compounds with limited data.

---

Peptide Safety Quick Reference

Peptide Class	Evidence Tier	Most Common Side Effects	Serious Risks	Long-Term Data
GLP-1 agonists (semaglutide, tirzepatide)	Tier 1 (FDA-approved)	Nausea, vomiting, diarrhea, constipation	Pancreatitis, gallbladder events, thyroid C-cell concern (rodents)	2+ years from trials, post-market data accumulating
Healing peptides (BPC-157, TB-500)	Tier 3 (preclinical)	Headache, nausea, injection site discomfort (user-reported)	Unknown -- no systematic human safety data	None in humans
GH secretagogues (CJC-1295, Ipamorelin)	Tier 3 (limited human data)	Water retention, tingling, joint stiffness, increased hunger	Elevated blood sugar, potential IGF-1/cancer association	Very limited
MK-677 (ibutamoren)	Tier 2-3 (some human data)	Increased appetite, water retention, elevated glucose	Impaired glucose tolerance, potential insulin resistance	Limited (1-2 year studies exist)

---

Frequently Asked Questions

What are the most common side effects of GLP-1 peptides?

Gastrointestinal effects: nausea, vomiting, diarrhea, and constipation. These occur in 20-40% of people at therapeutic doses, depending on the specific compound and dose. They are usually worst during the first few weeks and during dose increases, then improve over time. Slower dose titration reduces their severity. See: GLP-1 Side Effects: What to Expect.

Can peptides cause cancer?

For GLP-1 agonists: rodent studies showed thyroid C-cell tumors, but this has not been confirmed in humans. The boxed warning exists out of caution. Multiple large-scale human analyses have not found increased medullary thyroid carcinoma rates. For GH-related peptides: elevated IGF-1 levels have been associated with cancer risk in epidemiological studies, but a direct causal link has not been established. For research peptides: we do not have enough data to answer this question. See: Can Peptides Cause Cancer?.

Are research peptides like BPC-157 safe?

We cannot say definitively. BPC-157 has shown a favorable safety profile in animal studies, and anecdotal human reports generally describe it as well-tolerated. But there are no completed, peer-reviewed human clinical trials establishing its safety profile. "Generally well-tolerated in animal studies" and "proven safe for human use" are different statements. If you choose to use BPC-157 or other research peptides, doing so under medical supervision with regular monitoring is the most responsible approach.

Can I drink alcohol while on semaglutide or tirzepatide?

There is no absolute ban, but caution is warranted. Alcohol can worsen nausea, increase hypoglycemia risk, cause dehydration, and many users report dramatically reduced alcohol tolerance on GLP-1 agonists. Heavy drinking combined with GLP-1 use is inadvisable given the shared pancreatitis risk. Moderate consumption may be acceptable for some people -- discuss with your prescriber. See: Can You Drink Alcohol on Semaglutide?.

Can I use peptides during pregnancy?

No. GLP-1 agonists are contraindicated during pregnancy. Animal studies have shown fetal harm. Semaglutide should be stopped at least 2 months before a planned pregnancy. No research peptides have published reproductive safety data. The safe approach: stop all peptides before trying to conceive and discuss timing with your physician.

What bloodwork should I get before starting peptides?

At minimum: comprehensive metabolic panel (kidney/liver function, glucose, electrolytes), HbA1c, lipid panel, thyroid function (TSH, free T3, free T4), and CBC. If using GH secretagogues, add IGF-1. Get baseline labs before starting, then recheck every 3-6 months. Your physician may recommend additional tests based on your medical history.

How do I know if my peptide source is legitimate?

For prescription peptides: use a licensed pharmacy and verify its license through your state board. For compounded peptides: confirm the pharmacy is properly registered (ideally 503B). For research peptides: request a third-party Certificate of Analysis showing HPLC purity testing (98%+) and endotoxin testing. Avoid suppliers who make medical claims or cannot provide batch-specific COAs.

Do peptides interact with my other medications?

GLP-1 agonists slow gastric emptying, which can affect absorption of oral medications, particularly those with narrow therapeutic windows (oral contraceptives, levothyroxine, certain antibiotics). If you are on insulin or other blood sugar-lowering medications, adding a GLP-1 agonist often requires dose adjustments to prevent hypoglycemia. Always give your prescriber a complete list of your current medications before starting any peptide.

What should I do if I experience a serious side effect?

Stop the peptide immediately. Seek medical attention. Once stable, report the event to the FDA through MedWatch (1-800-FDA-1088 or online). You do not need to prove causation to file a report. For emergencies (severe allergic reaction, difficulty breathing, persistent severe abdominal pain, signs of severe dehydration), call 911 or go to the nearest emergency room.

Is long-term peptide use safe?

For GLP-1 agonists: published data extends to about 2 years, with post-market surveillance accumulating. The SELECT trial showed cardiovascular benefit for semaglutide, which is a positive long-term signal. But we do not have 10+ year data. For research peptides: there is no meaningful long-term human safety data. Honest answer: we do not know. This uncertainty is a factor that should inform your decision-making, not be ignored.

Are there peptides I should avoid completely?

Avoid any peptide from an unverified source without third-party testing. Beyond sourcing, specific medical contraindications matter more than blanket avoidance lists. People with a history of medullary thyroid carcinoma should not use GLP-1 agonists. People with active pancreatitis should not use GLP-1 agonists. People with poorly controlled diabetes should approach GH secretagogues cautiously. The "should I avoid this" question is always best answered by a physician who knows your full medical history.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. See our full medical disclaimer.

---

Sources

1. STEP 1-5 Trial Program (semaglutide safety data) -- Multiple publications, NEJM and JAMA, 2021-2023.
2. SURMOUNT 1-5 Trial Program (tirzepatide safety data) -- Multiple publications, NEJM and Lancet, 2022-2024.
3. SELECT Trial -- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." NEJM, 2023.
4. FDA Prescribing Information -- Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide).
5. GLP-1 receptor agonists and thyroid C-cell tumors -- Bjerre Knudsen L, et al. "Glucagon-like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells." Endocrinology, 2010.
6. MK-677 and glucose metabolism -- Nass R, et al. "Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults." Annals of Internal Medicine, 2008.
7. BPC-157 safety review -- Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157." Current Neuropharmacology, 2016. PMID: 27142294.
8. American Society of Anesthesiologists -- Guidance on GLP-1 Receptor Agonists and Elective Surgery, 2023.
9. FDA MedWatch -- Safety Reporting Portal. fda.gov/safety/medwatch.
10. IGF-1 and cancer risk -- Key TJ, et al. "Insulin-like growth factors and cancer risk." British Journal of Cancer, 2021.